ORDERING GUIDE

ORDERING OPTIONS FOR FLEXBUMIN®
5% AND 25% CONCENTRATIONS

Flexbumin
[Albumin (Human)], USP, 5% and 25% Solutions

FLEXBUMIN [ALBUMIN (HUMAN)] IS AVAILABLE IN THREE CARTON SIZES WITH TWO CONCENTRATIONS TO HELP MEET YOUR CENTER'S NEEDS

FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution[1]

SIZE	EQUIVALENT UNITS (EU)	ORDERING CODE*	NDC NUMBER (BOX)	NDC NUMBER (BAG)	PACK FACTOR	CONTAINER DIMENSIONS	SHIPPING WEIGHT
50 mL (12.5 g)	1	2G0201	0944-0493-01	0944-0493-03	24	12" x 6" x 2.5"	4.2 lb
100 mL (25 g)	2	2G0012	0944-0493-02	0944-0493-04	12	12" x 6" x 2.5"	4.2 lb

FLEXBUMIN 5% [Albumin (Human)], USP, 5% Solution[2]

SIZE	EQUIVALENT UNITS (EU)	ORDERING CODE*	NDC NUMBER (BOX)	NDC NUMBER (BAG)	PACK FACTOR	CONTAINER DIMENSIONS	SHIPPING WEIGHT
250 mL (12.5 g)	1	2G0250	0944-0495-05	0944-0495-06	10	12" x 6" x 2.5"	7 lb
250 mL (12.5 g)	1	2G025YC†	0944-0495-05	0944-0495-06	10	12" x 6" x 2.5"	7 lb

*Product ordering code to be used only when ordering directly from Takeda.
†Use this code to receive Y connector sets at no charge with your order. You will receive 5 Y connector sets per case (10 bags/case). Only available at Takeda.

THREE WAYS TO ORDER FLEXBUMIN:

Takeda e-commerce store by visiting **Store.Takeda.com**

Directly from your distributor or specialty pharmacy

Directly from Takeda by calling **1-800-423-2090**

For more information about FLEXBUMIN, visit FLEXBUMIN.com, contact your Takeda Representative, or contact Takeda Customer Service by phone at 1-800-423-2090.

INDICATIONS AND LIMITATION OF USE

FLEXBUMIN 5% and 25% are indicated for hypovolemia, hypoalbuminemia (burns), and cardiopulmonary bypass surgery. Albumin is not indicated as an intravenous nutrient.

FLEXBUMIN 25% is also indicated for hypoalbuminemia due to Adult Respiratory Distress Syndrome (ARDS) and nephrosis, and for hemolytic disease of the newborn (HDN).

IMPORTANT SAFETY INFORMATION

Contraindications

- History of hypersensitivity reaction to albumin preparations or to any of the excipients (N-acetyltryptophan and sodium caprylate). Reactions have included anaphylactic shock, anaphylactic reaction, or hypersensitivity/allergic reactions.
- Severe anemia or cardiac failure with normal or increased intravascular volume.

Please see additional Important Safety Information on the next page and click for Full Prescribing Information for FLEXBUMIN 5% and FLEXBUMIN 25%.

Flexbumin

[Albumin (Human)], USP, 5% and 25% Solutions

FLEXBUMIN IS IN A FLEXIBLE, SHATTER-PROOF CONTAINER FREE OF LATEX, PVC, DEHP, AND DEHA, THAT CREATED A STORAGE EFFICIENCY OF AT LEAST 57%[3,4*]

DEHA=diethylhexyl adipate; DEHP=diethylhexyl phthalate; PVC=polyvinyl chloride.
*Calculations were based on an Omnicell dispensing cabinet and comparison of FLEXBUMIN 25% 50 mL and 100 mL containers and FLEXBUMIN 5% 250 mL containers with containers of BUMINATE® [Albumin (Human)], USP, 5% and 25% Solutions in glass bottles of equal volume.

50 mL (25% solution) | 100 mL (25% solution) | 250 mL (5% solution)

IMPORTANT SAFETY INFORMATION (CONTINUED)

Warnings and Precautions

Hypersensitivity Reactions: Have been observed (including anaphylactic reactions). If hypersensitivity reaction is suspected, discontinue administration immediately and implement appropriate standard medical treatment.

Hypervolemia/Hemodilution: Under conditions where hypervolemia and/or hemodilution may occur, adjust the dose and rate of infusion to the patient's volume status. When administering large volumes, monitor hemodynamic parameters. Ensure adequate substitution of other blood constituents and monitor electrolyte balance. Discontinue administration at the first clinical signs of cardiovascular overload.

Hemodynamics: Closely monitor hemodynamic parameters after administration for evidence of cardiac or respiratory failure, renal failure, or increasing intracranial pressure.

Blood Pressure: Monitor blood pressure in trauma patients and postoperative surgery patients in order to detect re-bleeding secondary to clot disruption.

Hemolysis: Do not dilute with Sterile Water for Injection, as there is potential risk of fatal hemolysis and acute renal failure in recipients.

Transmission of Infectious Agents: Because FLEXBUMIN 5% and 25% are made from human plasma, they may carry a risk of transmitting infectious agents (e.g., viruses, other pathogens). No cases of transmission of viral diseases, Creutzfeldt-Jakob disease (CJD) or variant Creutzfeldt-Jakob disease (vCJD) have ever been identified.

Adverse Reactions

The most serious adverse reactions are hypersensitivity reaction (including anaphylactic reaction) and pulmonary edema.

Administration Caution

Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

Please click for Full Prescribing Information for FLEXBUMIN 5% and FLEXBUMIN 25%.

References: 1. FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2023. **2.** FLEXBUMIN 5% [Albumin (Human)], USP, 5% Solution. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2023. **3.** Data on file. VV-MED-7449—Certificate of non-use: concerned chemicals for environment. **4.** Data on file. GALAXY storage space comparisons.

US-FLE-0118v1.0 10/24